Pharvaris presents deucrictibant data at allergy conference

Pharvaris N.V. (NASDAQ: PHVS) presented clinical trial data for its oral drug deucrictibant at the American Academy of Allergy, Asthma & Immunology 2026 Annual Meeting held February 27 through March 2 in Philadelphia.

The company's Phase 3 RAPIDe-3 study met its primary endpoint and all 11 secondary efficacy endpoints. The trial evaluated deucrictibant immediate-release capsules (20 mg) for treating hereditary angioedema (HAE) attacks in participants 12 years and older. Patients receiving deucrictibant experienced symptom relief in a median time of 1.28 hours compared to over 12 hours with placebo. Complete symptom resolution occurred in 11.95 hours with deucrictibant versus over 48 hours with placebo.

The study showed that 90.4% of deucrictibant-treated attacks achieved symptom relief within 12 hours, compared to 48.3% of placebo-treated attacks. For complete resolution within 48 hours, 81.9% of deucrictibant-treated attacks met this endpoint versus 36.8% of placebo-treated attacks.

Final data from the CHAPTER-1 open-label extension study demonstrated long-term safety and efficacy for deucrictibant prophylaxis over approximately three years. The mean attack rate decreased from 2.18 attacks per month at baseline to 0.12 attacks per month during the extension period. Approximately half of participants remained attack-free during the extension study.

Phase 1 data showed that deucrictibant extended-release tablets maintained therapeutic exposure for at least 24 hours, supporting once-daily dosing for prophylactic treatment. The company is preparing marketing authorization applications for the immediate-release formulation and conducting the ongoing Phase 3 CHAPTER-3 study for the extended-release tablet, with results expected in the third quarter of 2026.

Deucrictibant has received orphan drug designation for bradykinin-mediated angioedema treatment from the FDA, European Commission, and Swissmedic. The information is based on a company press release.

You May Also Be Interested In

• Trump highlights ibogaine development push, Psyence BioMed responds
• Baxter raises tender offer cap to $600M for senior notes
• Better Home & Finance sues former CEO Vishal Garg over securities claims